1999 Canadian recommendations for the management of hypertension

CMAJ. Canadian Medical Association Journal

Volumn 161, Issue 12 SUPPL., 1999, Pages

  Feldman, Ross D ^a   Campbell, Norman ^b   Larochelle, Pierre ^c   Bolli, Peter ^d   Burgess, Ellen D ^e   Carruthers, S George ^d   Floras, John S ^f   Haynes, R Brian ^g   Honos, George ^h   Leenen, Frans H H ⁱ   Leiter, Larry A ^f   Logan, Alexander G ^f   Myers, Martin G ^f   Spence, J David ^d   Zarnke, Kelly B ^d  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; COMORBIDITY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; GOUT; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HOME MONITORING; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; REVIEW;

EID: 0033554826     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10(10 Pt 1):1097-102.
2. Carruthers SG, Larochelle P, Haynes RB, Petrsovits A, Schiffrin EL. Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. CMAJ 1993;149(3):289-93.
3. Haynes RB, Lacourcière Y, Rabkin SW, Leenen FHH, Logan AG, Wright N, et al. Report of the Canadian Hypertension Society Consensus Conference: 2. Diagnosis of hypertension in adults. CMAJ 1993;149(4):409-18.
4. Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA, Myers MG. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension. CMAJ 1993;149(5):575-84.
5. Reeves RA, Fodor JG, Gryfe CI, Patterson C, Spence JD. Report of the Canadian Hypertension Society Consensus Conference: 4. Hypertension in the elderly. CMAJ 1993;149(6):815-20.
6. Dawson KG, McKenzie JK, Ross SA, Chiasson JL, Hamet P. Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes. CMAJ 1993;149(6):821-6.
7. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997;157(6):715-25.
8. Moutquin JM, Garner PR, Burrows RF, Rey E, Helewa ME, Lange IR, et al. Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmcologic management and prevention of hypertensive disorders in pregnancy. CMAJ 1997;157 (7):907-19.
9. Rey E, LeLorier J, Burgess E, Lange IR, Leduc L. Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ 1997;157(9):1245-54.
10. Campbell NRC, Burgess E, Choi BCK, Taylor G, Wilson E, Cléroux J, et al. Lifestyle modifications to prevent and control hypertension: 1. Methods and overview of the Canadian recommendations. CMAJ 1999;160(9 suppl):S1-S6.
11. Leiter LA, Abbott D, Campbell NRC, Mendelson R, Ogilvie RI, Chockalingam A. Lifestyle modifications to prevent and control hypertension: 2. Recommendations on obesity and weight loss. CMAJ 1999;160(9 suppl):S7-S12.
12. Campbell NRC, Ashley MJ, Carruthers SG, Lacourcière Y, McKay DW. Lifestyle modifications to prevent and control hypertension: 3. Recommendations on alcohol consumption. CMAJ 1999;160(9 suppl):S13-S20.
13. Cléroux J, Feldman RD, Petrella RJ. Lifestyle modifications to prevent and control hypertension: 4. Recommendations on physical exercise training. CMAJ 1999;160(9 suppl):S21-S28.
14. Fodor JG, Whitmore B, Leenen F, Larochelle P. Lifestyle modifications to prevent and control hypertension: 5. Recommendations on dietary salt. CMAJ 1999; 160(9 suppl):S29-S34.
15. Burgess E, Lewanczuk R, Bolli P, Chockalingam A, Cutler H, Taylor G, et al. Lifestyle modifications to prevent and control hypertension: 6. Recommendations on potassium, magnesium and calcium. CMAJ 1999;160(9 suppl):S35-45.
16. Spence JD, Barnett PA, Linden W, Ramsden V, Taenzer P. Lifestyle modifications to prevent and control hypertension: 7. Recommendations on stress management. CMAJ 1999;160 (9 suppl):S46-S50.
17. Myers MG, Oh PI, Reeves RA, Joyner CD. Prevalence of white coat effect in treated hypertensive patients in the community. Am J Hypertens 1995;8:591-7.
18. McKay DW, Campbell NR, Parab LS, Chockalingam A, Fodor JG. Clinical assessment of blood pressure. J Hum Hypertens 1990;4:639-45.
19. Rosner B, Polk F. Predictive values of routine blood pressure measurements in screening for hypertension.Am J Epidemiol 1983;117:429-42.
20. Perry HM, Miller JP. Difficulties in diagnosing hypertension: implications and alternatives. J Hypertens 1992;10:887-96.
21. Brueren MM, Petri H, van Weel C, van Ree JW. How many measurements are necessary in diagnosing mild to moderate hypertension. Fam Pract 1997;14:130-5.
22. Haynes RB, Sackett DL, Gibson ES. Improvement of medication compliance in uncontrolled hypertension. Lancet 1976;1:1265-8.
23. Johnson AL, Taylor DW, Sackett DL. Self-recording of blood pressure in the management of hypertension. CMAJ 1978;119:1034-9.
24. Sawicki P, Muhlhauser I, Didjurgeit U. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy. J Hypertens 1995;13:933-8.
25. de Gaudemaris R, Chau NP, Mallion J-M. Home blood pressure: variability, comparison with office readings and proposal for reference values. J Hypertens 1994;12:831-8.
26. Tsuji I, Imai Y, Nagai K, Ohkubo T, Watanabe N, Minami N, et al. Proposal of reference values for home blood pressure measurement. Prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens 1997;10:409-18.
27. Imai Y, Satoh H, Nagai K. Characteristics of a community-based distribution of home blood pressure in Ohasama in northern Japan. J Hypertens 1993;11:1441-9.
28. Thijs L, Staessen JA, Celis H, de Gaudemaris R, Imai Y, Julius S, et al. Reference values of self-recorded blood pressure: a meta-analysis of summary data. Arch Intern Med 1998;158:481-8.
29. Campbell N, Abbott D, Bass M, Birkett NJ, Chockalingam A, Dagenais GR, et al. Self-measurement of blood pressure: recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Can J Cardiol 1995;11:5H-10H.
30. McKay DW, Campbell NR, Chockalingam A, Ku L, Small C, Wasi S. Self-measurement of blood pressure: assessment of equipment. Canadian Coalition for High Blood Pressure Prevention and Control. Can J Cardiol 1995;11(suppl H):29H-34H.
31. Association for the Advancement of Medical Instrumentation. American National Standard for Electronic or Automated Sphygmomanometers: ANSI/AAMI SP10-1987. (25). 1987. 3330 Washington Boulevard, Suite 400, Arlington, VA 22201-4598.
32. O'Brien E, Petrie J, Littler W. Short report: an outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J Hypertens 1993;11:677-9.
33. Ohkubo T, Imai Y, Tsuji I. Prediction of mortality by ambulatory blood pressure monitoring versus screening blood pressure measurements: a pilot study in Ohasama. J Hypertens 1997;15:357-64.
34. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994;24:793-801.
35. Pickering T. Recommendations for the use of home (self) and ambulatory blood pressure monitoring. A m J Hypertens 1995;9:1-11.
36. Myers MG. The white-coat effect in treated hypertension. Blood Pressure Monitoring 1996;1:247-9.
37. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. JAMA 1997;278:1065-72.
38. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
39. Gottdiener JS, Livengood SV, Meyer PS, Chase GA. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol 1995;25:424-30.
40. Herpin D, Demange J. Effect of regression to the mean in serial echocardiographic measurements of left ventricular mass. Quantification and clinical implications. Am J Hypertens 1994;7:824-8.
41. Rakowski H. Canadian consensus recommendations for the measurement of reporting of diastolic dysfunction by echocardiography. J Am Soc Echocardiogr 1996;9:736-60.
42. Task Force of the Echocardiography section of the Canadian Cardiovascular Society and Canadian Hypertension Society. Guidelines from the Canadian Cardiovascular Society and the Canadian Hypertension Society task force on the echocardiographic determination of left ventricular mass. Can J Cardiol 1995;11:391-5.
43. Anderson KM, Wilson PWF, Odell PW, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
44. Jackson R, Barham P, Bills J, Birch T, McLennan L. Management of raised blood pressure in New Zealand. A discussion document. BMJ 1993;307:107-10.
45. Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? Arch Intern Med 1996;156:1414-20.
46. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6.
47. Comeau DG, Sketris I, Kephart GC, Bata IR, Wolf HK. The change in composition and cost of antihypertensive drug treatment between 1985 and 1995 in the Halifax County MONICA area. Circulation 1998;97:826.
48. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
49. Forette F, Seux ML, Staessen J, Thij L, Birkenhager WH, Babarskeine MR. et al. Prevention of dementia in the SYST-EUR trial. Lancet 1998;352:1347-51.
50. Joffres MR, Hamet P, Rabkin SW, Gelskey D, Hogan K, Fodor G. Prevalence, control and awareness of high blood pressure among Canadian adults. CAMJ 1992;146:1997-2005.
51. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (SYST-EUR) Trial Investigators. Lancet 1997;350:757-64.
52. Forette F, Rigaud AS, Morin M, Gisselbrecht M, Bert P. Assessing vascular dementia. Neth J Med 1995;47:185-94.
53. Kuwajima I, Hoh E, Suzuki Y, Matsushita S, Kuramoto K. Pseudohypertension in the elderly. J Hypertens 1990;8:429-32.
54. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ebkom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
55. Coope J, Warrender TS. Randomized trial of treatment of elderly patients in primary care. EMJ 1986;293:1145-8.
56. Amery A, Birkenhager WH, Brixko P, Bulpitt C, Clement D, Deruyttere M et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1985;1:1349-54.
57. Management Committee. Treatment of mild hypertension in the elderly. Med J Aust 1981;2:398-400.
58. Gong L, Shang W, Zhu Y, Jo G, II collaborating centers in the Shanghai area (Shanghai Institute of Hypertension Rui Jin Hospital of Shanghai in China), Kong D, et al. Shanghai trial of nifedipine in the elderly. J Hypertens 1996;14:1-9.
59. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
60. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
61. Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Can J Cardiol 1998;14(suppl A):17A-21A.
62. Grimm Jr RH, Flack JM, Grandits GA, Elmer PJ, Neaton, JN, Cutler JA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996;275:1549-56.
63. Buhler FR, Vesanen K, Watters JT, Bolli P. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. Am Heart J 1988;115:282-7.
64. Greenberg G, Thompson SG, Brennan PJ. The relationship between smoking and the response to antihypertensive treatment in mild hypertensives in the Medical Research Council's trial of treatment. Int J Epidemiol 1987;16:25-30.
65. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J et al. Beta-blocker versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72.
66. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-939.
67. Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetes Care 1996;19:305-12.
68. Skyler JS, Marks JB, Schneiderman N. Hypertension in patients with diabetes mellitus. Am J Hypertens 1995;8:100s-105s.
69. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93.
70. Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991;14 (suppl 4):13-26.
71. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
72. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81-7.
73. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-43.
74. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. AmJ Med 1995;99:497-504.
75. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996;39:587.
76. Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129-38.
77. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
78. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.
79. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitus (a 7 year follow-up study). Arch Intern Med 1996;156:286-89.
80. Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, et al. Effects of long-term enalapril treatment on persistent microalbuminuria in well controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994;17:420-4.
81. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
82. Curb JD, Pressel SL, Cutler JA, Savage, PJ, Applegate WB, Black H et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older persons with isolated systolic hypertension. JAMA 1996;276:1886-92.
83. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J MeJ 1999;340:677-84.
84. Olsson G, Wikstrand J, Warnold I, Manger Cats V, McBoyle D, Herlitz J, et al. Metoprolol-induced reduction in post infarction mortality: pooled results from five double-blind randomized trials. Eur Heart J 1992;13:28-32.
85. Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997;39:445-6.
86. Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, et al. Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997;95:2368-73.
87. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction. Am J Cardiol 1990;66: 779-85.
88. The Multicenter Diltiazem Post-Infarction Trial Research Group. The effect of diltiazem on mortality and re-infarction after myocardial infarction. N Engl J Med 1998;319: 385-92.
89. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202-12.
90. Gustafsson F, Kober L, Torp-Pedersen C, Hildebrandt P for the Trandolapril Cardiac Evaluation study. Influence of a history of arterial hypertension and pretreatment blood pressure on the effect of angiotensin converting enzyme inhibition after acute myocardial infarction. J Hypertens 1998; 16 (suppl 1):S65-S70.
91. Kostis JB. The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens 1995;8:909-14.
92. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997;15:3-17.
93. Bourassa MG, Gurne O, Bangdiwala SL, Ghali JK, Young JB, Rousseau M et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22:14A-19A.
94. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
95. Pitt B, Zannad F, Remme WJ, Cody R, Catuigne A, Perez A. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341;709-17.
96. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of the Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52.
97. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.
98. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
99. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
100. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
101. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERTT_HF). Lancet 1999;353:2001-7.
102. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
103. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation 1997;96:856-63.
104. Bagger JP, Helligsoe P, Randsbaek F, Kimose HH, Jensen BS. Effect of verapamil in intermittent claudication. A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. Circulation 1997;95:411-4.
105. Van de Ven LL, Van Leeuwen JT, Smit AJ. The influence of chronic treatment with beta-blockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa 1994;23:357-62.
106. van de Ven PJG, Beutler JJ, Kaatee, Beek FJ, Mail WP, Koomans HA. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int 1998;53:986-93.
107. Franssen C, Wollersheim H, de Haan A, Thien T. The influence of different beta-blocking drugs on the peripheral circulation in Raynaud's phenomenon and in hypertension. J Clin Pharmacol 1992;32:652-9.
108. Pancera P, Sansone S, Secchi S, Covi G, Lechi A. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon. J Intern Med 1997;242:373-6.
109. Golzari H, Cebul RD, Bahler RC. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996;125:311-23.
110. McKibbin JK, Pocock WA, Barlow JB, Millar RN, Obel IW. Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J 1984;51:157-62.
111. Strandgaard S. Hypertension and stroke. J Hypertens 1996;14 (suppl 3):S23-S27.
112. Dyker AG, Grosset DG, Lees K. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke 1997;28:580-583.
113. Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997;28:2557-662.
114. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP, et al: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
115. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
116. Langenfeld MR, Gatzka CD, Weidinger G, Schobel HP. Impact of alpha versus beta-blockers on hypertensive target organ damage: results of a double-blind, randomized, controlled clinical trial. Am J Hypertens 1997;10:985-91.
117. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH Jr, Neaton JD, et al. Comparison of five annhypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995;91:698-706.
118. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997;95:2007-14.
119. Ofili ED, Cohen JD, Stvrain JA, Pearson A, Martin TJ, Uy ND, et al. Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA 1998;279:778-80.
120. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
121. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15.
122. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal insufficiency: role of blood pressure. Kidney Int 1989;35:670-4.
123. Kes P, Ratkovic-Gusic I. The role of arterial hypertension in progression of renal failure. Kidney Int 1996;49 (suppl 55):S72-S74.
124. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
125. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995;123:754-62.
126. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939-45.
127. Locatelli F, Carbarns IRI, Machio G, Mann JFE, Ponticelli C, Ritz E, et al. Long-term progression of chronic renal insufficiency in the AIPRI extension study. Kidney Int 1997;52(suppl 63):S63-S66.
128. The GISEN Group. Randomized placebo-contolled trial of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-63.
129. Hannedouche T, Landais P, Goldfarb B, EI Esper N, Fournier A, Godin M, et al. Randomised controlled trial of enalapril and beta-blockers is non-diabetic chronic renal failure.BMJ 1994;309:833-7.
130. Toto RD, Mitchell HC, Smith RD, Le HC, McIntire D, Pettinger WA. "Strict" blood pressure control and the progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995;48:851-9.
131. Burgess E. Conservative treatment to slow deterioration of renal function: evidence-based recomendations. Kidney Int 1999;55(suppl 70):S17-S25.
132. Ruggenenti P, Perna A, Gherdi G, Benini R, Remuzzi G, on behalf of the Gruppo Itiliano di Studi Epidemiologici in Nephrologia (GISEN). Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998;352:1252-6.
133. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42:452-8.
134. Blanchi S, Bigazzi R, Baldari G, Campese VM. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up. Am J Nepbrol 1991;11:131-7.
135. Graft DF, Fowles J, McCoy CE, Lager RA. Detection of beta-blocker use in people with asthma. Ann Allergy 1992;69:449-53.
136. Holmes B, Sorkin EM. Indoramin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular, and airway diseases. Drugs 1986;31:467-99.
137. Lofdahl CG. Antihypertensive drugs and airway function, with special reference to calcium channel blockade. J Cardiovasc Pharmacol 1989;14(suppl 10):S40-S51.
138. Lindgren BR, Andersson RGG. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med Toxicol Adverse Drug Exp 1989;4:369-80.
139. Lunde H, Hedner T, Samuelsson O, Lotvall J, Andren L, Lindholm L, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994;308:18-21.
140. Waller PC, Ramsay LE. Predicting acute gout in diuretic-treated hypertensive patients. J Hum Hypertens 1980;3:457-61.
141. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13.
142. Emmerson BT. Atherosclerosis and urate metabolism. Austr N Z J Med 1979;9:451-4.
143. Tweeddale MG, Fodor JG. Elevated serum uric acid. A cardiovascular risk factor? Nephron 1979;23(suppl 1):3-7.
144. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998;352:670-1.
145. Beevers DG, Lip GY. Is uric acid really an independent cardiovascular risk factor? Lancet 1998;352:1556.